[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IS4805A - Method of treatment and pharmaceutical composition - Google Patents

Method of treatment and pharmaceutical composition

Info

Publication number
IS4805A
IS4805A IS4805A IS4805A IS4805A IS 4805 A IS4805 A IS 4805A IS 4805 A IS4805 A IS 4805A IS 4805 A IS4805 A IS 4805A IS 4805 A IS4805 A IS 4805A
Authority
IS
Iceland
Prior art keywords
treatment
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
IS4805A
Other languages
Icelandic (is)
Inventor
Dahlen Sven-Erik
M. Scolnick Edward
Rahway
Original Assignee
Merck & Co., Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en
Application filed by Merck & Co., Inc filed Critical Merck & Co., Inc
Publication of IS4805A publication Critical patent/IS4805A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS4805A 1996-02-08 1998-07-22 Method of treatment and pharmaceutical composition IS4805A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1132896P 1996-02-08 1996-02-08
GBGB9608927.1A GB9608927D0 (en) 1996-04-29 1996-04-29 Method of treatment and pharmaceutical composition
PCT/US1997/001799 WO1997028797A1 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composion

Publications (1)

Publication Number Publication Date
IS4805A true IS4805A (en) 1998-07-22

Family

ID=26309231

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4805A IS4805A (en) 1996-02-08 1998-07-22 Method of treatment and pharmaceutical composition

Country Status (19)

Country Link
EP (1) EP1014972A4 (en)
JP (1) JPH11504044A (en)
KR (1) KR19990082367A (en)
CN (1) CN1210465A (en)
AU (1) AU732671B2 (en)
BG (1) BG102669A (en)
BR (1) BR9707369A (en)
CA (1) CA2245162A1 (en)
CZ (1) CZ248798A3 (en)
EE (1) EE9800234A (en)
IL (1) IL125446A0 (en)
IS (1) IS4805A (en)
NO (1) NO983641D0 (en)
NZ (1) NZ331160A (en)
PL (1) PL328074A1 (en)
SK (1) SK105698A3 (en)
TR (1) TR199801511T2 (en)
WO (1) WO1997028797A1 (en)
YU (1) YU33298A (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
DE69835103T2 (en) * 1997-12-23 2006-12-21 Schering Corp. COMPOSITION FOR THE TREATMENT OF AIRWAY AND GUM DISEASES WITH AT LEAST ONE LEUKOTRIENANT AGONIST AND AT LEAST ONE ANTI-HISTAMINIC
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
ID29137A (en) * 1998-07-27 2001-08-02 Schering Corp HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
AR022378A1 (en) * 1998-09-10 2002-09-04 Schering Corp METHODS AND COMPOSITIONS TO TREAT SINUSITIS, MEDIUM OTITIS AND OTHER RELATED DISORDERS USING ANTIHISTAMINS
WO2000057880A1 (en) * 1999-03-29 2000-10-05 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (en) 2000-02-17 2001-08-23 Asta Medica Ag Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist
WO2002036124A2 (en) * 2000-10-30 2002-05-10 Schering Corporation Treatment and method using loratadine and montelukast
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
WO2004087095A2 (en) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Osmotic controlled release device containing zafirlukast and an h1-antagonist
EP1680084A2 (en) * 2003-10-21 2006-07-19 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
WO2005089748A1 (en) * 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
MX2007004976A (en) 2004-10-25 2007-06-14 Schering Corp M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders.
TR200806298A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Pharmaceutical formulation
EP2443134A2 (en) 2009-06-16 2012-04-25 Schering Corporation NOVEL [3,2-c]HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
KR101540191B1 (en) * 2014-02-24 2015-07-28 성균관대학교산학협력단 Composition comprising Loratadine for anti-inflammation
TW202042813A (en) * 2019-01-10 2020-12-01 大陸商江陰貝瑞森製藥有限公司 New formulations containing leukotriene receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
WO1997028797A1 (en) 1997-08-14
CZ248798A3 (en) 1999-01-13
AU732671B2 (en) 2001-04-26
NO983641L (en) 1998-08-07
NZ331160A (en) 2000-07-28
EP1014972A1 (en) 2000-07-05
EE9800234A (en) 1998-12-15
EP1014972A4 (en) 2004-12-08
CA2245162A1 (en) 1997-08-14
JPH11504044A (en) 1999-04-06
YU33298A (en) 1999-11-22
SK105698A3 (en) 1999-05-07
BR9707369A (en) 1999-07-20
KR19990082367A (en) 1999-11-25
PL328074A1 (en) 1999-01-04
NO983641D0 (en) 1998-08-07
AU2257997A (en) 1997-08-28
TR199801511T2 (en) 1998-10-21
IL125446A0 (en) 1999-03-12
CN1210465A (en) 1999-03-10
BG102669A (en) 1999-04-30

Similar Documents

Publication Publication Date Title
IS4805A (en) Method of treatment and pharmaceutical composition
DK0890359T3 (en) Beta-Lactam antibiotic-containing tablets and method of preparation thereof
BR9407799A (en) Composition of matter treatment method and pharmaceutical composition
NO994778D0 (en) Methods and compositions for the treatment of intestinal inflammation
DK139696A (en) Bone rail and method of making them
NO975759D0 (en) Inoculant and Method of Preparation of Inoculant
NO973365D0 (en) Method of baking and associated device
DK1079809T3 (en) Enteric coated pharmaceutical composition and method of preparation thereof
DK1041879T4 (en) Disinfectant and method of manufacture
NO970532D0 (en) System and method of blood treatment
NO974671L (en) Method of isolating a protein composition from a muscle source and protein composition
IS4720A (en) Method and pharmaceutical composition for controlling lipid concentration
DK0926952T3 (en) Antimicrobial composition and process for its preparation
DK0815922T3 (en) Desulfurization and decarbonisation process
DK91793A (en) Method of surface treatment, means of application and its use
IS4466A (en) Composition and treatment for multiple sclerosis
BR9709450A (en) Inhibitors of s-cd23 production and tnt secretion
NO995034D0 (en) Dental implant system and method of manufacture thereof
DK0735042T3 (en) Maltitol composition and process for its preparation
IS4779A (en) Method of producing felodipine and method of producing a pharmaceutical composition
BR9710544A (en) Composite treatment method and pharmaceutical composition
NO20001758D0 (en) Methods and compositions for the treatment of arthritis
DE69717846D1 (en) TREATMENT METHOD OF LACTATAS
NO963366D0 (en) Peptides and method of treating diabetes
DK0915655T3 (en) Method and composition for the treatment of parasites in animal environments